Ascentage Pharma Announces Five Abstracts To Be Presented at the 2018 American Association for Cancer Research Annual Meeting

Ascentage Pharma Announces Five Abstracts To Be Presented at the 2018 American Association for Cancer Research Annual Meeting

Promising results targeting multiple pathways of apoptosis with novel small molecules

ROCKVILLE, Md. and HONG KONG, April 12, 2018 /PRNewswire/ -- Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that research on its pipeline of small molecule therapeutics will be presented at the 2018 American Association for Cancer Research (AACR) annual meeting in Chicago, April 14-18, 2018.

"The work we're presenting at AACR this year focuses on the translational research of our investigational compounds currently in clinical trials. These studies led to the identification of promising combination approaches, discovery of new indications, as well as a better understanding of their mechanisms. This knowledge has helped us accelerate our drug discovery efforts and provides support for our ongoing clinical trials." commented Dr. Dajun Yang, Chairman and CEO of Ascentage.

AACR abstracts include:

    --  Title: Targeting the Anti-Apoptotic BCL-2 Family Protein Provides an
        Effective and Precise Therapeutic Strategy for NHL  Session Title: BCL-2
        Family and Mitochondrial Apoptosis Session Date and Time: Sunday, April
        15, 2018 1:00 PM - 5:00 PM CDTPoster Number: 301




    --  Title: Targeting BCL-2 and BCL-xL With a Novel Dual Inhibitor APG-1252
        Triggers Cell Death and Inhibits Tumor Growth in Small Cell Lung Cancer
        Models Session Title: BCL-2 Family and Mitochondrial ApoptosisSession
        Date and Time: Sunday, April 15, 2018 1:00 PM - 5:00 PM CDTPoster
        Number: 307




    --  Title: A Novel MDM2-p53 Antagonist APG-115 Induces p53-Mediated
        Apoptosis and Enhances Radiosensitivity in Colorectal Cancer Session
        Title: BCL-2 Family and Mitochondrial Apoptosis Session Date and Time:
        Sunday, April 15, 2018 1:00 PM - 5:00 PM CDTPoster Number: 314




    --  Title: HQP1351, A Novel Multikinase Inhibitor in Clinical Development,
        Overcomes Drug Resistance for the Treatment of Gastrointestinal Stromal
        Tumors in Preclinical Models Session Title: Therapeutic Resistance: New
        Targets and New InhibitorsSession Date and Time: Monday, April 16, 2018
        8:00 AM - 12:00 PM CDTPoster Number: 1979



    --  Title: SMAC Mimetics APG-1387 Synergizes with Immune Checkpoint
        Inhibitors in Preclinical Models Session Title: Modifiers of the Tumor
        Microenvironment 2Session Date and Time: Monday, April 16, 2018 8:00 AM
        - 12:00 PM CDTPoster Number: 1754

About Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company's expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of seven clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.

Media Contact
Amy Bonanno
E-mail: abonanno@bmccommunications.com
Phone: +1 914 450 0349

Investor Contact
Chad Rubin
E-mail: crubin@troutgroup.com
Phone: +1 646 378 2947

View original content with multimedia:http://www.prnewswire.com/news-releases/ascentage-pharma-announces-five-abstracts-to-be-presented-at-the-2018-american-association-for-cancer-research-annual-meeting-300628780.html

SOURCE Ascentage Pharma